Company: SYRA
Filing Date: 2025-03-11
Form Type: 10-K
Source: 0001493152-25-009873
Chunk: 269

Company: Syra Health Corp
Filing Date: 2025-03-11
Form: 10-K
Item: Item 1A
Chunk 269
---
 in some of the products we offer. For example, some of our targeted education approaches include
the utilization of artificial intelligence tools to provide real-time information to customers, and we intend to offer an artificial
intelligence chatbot to facilitate and provide end-to-end query resolution for patients. The field of artificial intelligence is rapidly
developing, both technologically and from a regulatory and legal standpoint. As we incorporate this technology into our products we may
experience unexpected outcomes or impacts related to the technology, creating reputational, legal and regulatory risks.

Risks
Related to Intellectual Property

The
protection of our intellectual property requires substantial resources and protections of our proprietary rights may not be adequate.

We
rely or intend to rely upon a combination of trade secret, copyright and trademark laws, patents, license agreements, confidentiality
procedures, nondisclosure agreements and technical measures designed to protect the intellectual property used in our business. The steps
we have taken to protect and enforce our proprietary rights and intellectual property may not be adequate. For instance, our agreements
with employees, consultants and others who develop intellectual property for or on behalf of us could be breached and could result in
our trade secrets and confidential information being publicly disclosed. We may not have adequate remedies for any such breach. Third
parties also may infringe upon or misappropriate our intellectual property rights. If we believe a third party has misappropriated our
intellectual property, litigation may be necessary to enforce and protect those rights, which would divert management resources, could
be expensive and may not effectively protect our intellectual property. Even if we establish infringement, a court may decide not to
grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate
remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there
is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public
announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive
these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, there can
be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims. Even if we ultimately
prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel
could outweigh any benefit we receive as a